ORLANDO — At the ASH Annual Meeting and Exposition, Bryant Fields, senior director of integrated evidence at Acorn AI, a Medidata Solutions company, discusses the use of synthetic control arms in clinical trials.
Fields and his team were able to effectively replicate a control group using a synthetic approach in a multiple myeloma study.
“This represents another step in validating this approach to bring a treatment to the industry faster, but more importantly with a higher degree of scientific certainty to multiple myeloma patients and other indications we’re providing access to, in some cases, very lifesaving treatments faster,” Fields told HemOnc Today. – by Alaina Tedesco
Disclosure: Fields reports being a senior director at Medidata Solutions.